Retention Agreements in the Pharmaceuticals Industry
69 Contracts & Agreements
- Acasti Pharma Inc. (2 contracts)
- Akorn (1)
- Altus Pharmaceuticals Inc. (1)
- APP Pharmaceuticals, Inc. (2)
- Boston Therapeutics, Inc. (1)
- Cara Therapeutics, Inc. (1)
- Catalent Inc (1)
- ELITE PHARMACEUTICALS INC (3)
- Eloxx Pharmaceuticals, Inc. (5)
- Endo International plc (9)
- Endo Pharmaceuticals Solutions Inc. (3)
- IMARA Inc. (5)
- Innovive Pharmaceuticals, Inc. (1)
- Lannett Company, Inc. (1)
- Mallinckrodt (1)
- Nabriva Therapeutics plc (1)
- Notis Global, Inc. (1)
- OptiNose, Inc. (1)
- PENWEST PHARMACEUTICALS CO (2)
- PLx Pharma Inc. (2)
- SCICLONE PHARMACEUTICALS INC (9)
- Sienna Biopharmaceuticals, Inc. (5)
- Supernus Pharmaceuticals, Inc. (4)
- Tilray, Inc. (1)
- Trevi Therapeutics, Inc. (1)
- Tricida, Inc. (2)
- Upjohn Inc (2)
- VION PHARMACEUTICALS INC (1)
- Form of Retention Letter (Mallinckrodt, Filed With SEC on June 21, 2023)
- Form of Award Notice under PLx Pharma Inc. 2023 Key Executive Retention Plan (PLx Pharma Inc., Filed With SEC on February 13, 2023)
- PLx Pharma Inc. 2023 Key Executive Retention Plan (PLx Pharma Inc., Filed With SEC on February 13, 2023)
- Retention Agreement between Endo and Patrick Barry, dated August 11, 2022 (Endo International plc, Filed With SEC on November 9, 2022)
- Retention Agreement between Endo and Matthew J. Maletta, dated August 11, 2022 (Endo International plc, Filed With SEC on November 9, 2022)
- Retention Agreement between Endo and Mark T. Bradley, dated August 11, 2022 (Endo International plc, Filed With SEC on November 9, 2022)
- Retention Agreement between Endo and Blaise Coleman, dated August 11, 2022 (Endo International plc, Filed With SEC on November 9, 2022)
- Amendment to Amended and Restated Retention Agreement, dated as of May 18, 2022, by and between the Company and Michael P. Gray (IMARA Inc., Filed With SEC on September 7, 2022)
- Amendment to Retention Agreement, dated as of May 5, 2022, by and between the Company and Rahul D. Ballal, Ph.D (IMARA Inc., Filed With SEC on September 7, 2022)
- Form of Retention Award Letter (Lannett Company, Inc., Filed With SEC on August 25, 2022)
- Amended and Restated Retention Agreement, dated as of May 18, 2022, by and between the Registrant and Michael P. Gray (IMARA Inc., Filed With SEC on August 3, 2022)
- February 18, 2022 Retention Agreement with Douglas Plassche (ELITE PHARMACEUTICALS INC, Filed With SEC on June 29, 2022)
- Retention Agreement, dated as of May 5, 2022, by and between the Registrant and Michael P. Gray (IMARA Inc., Filed With SEC on May 6, 2022)
- Retention Agreement, dated as of May 5, 2022, by and between the Registrant and Rahul D. Ballal, Ph.D (IMARA Inc., Filed With SEC on May 6, 2022)
- Retention Agreement, dated March 7, 2022, between Michael F. Marino and Optinose US, Inc (OptiNose, Inc., Filed With SEC on March 8, 2022)
- Retention Agreement between Endo and Patrick Barry, dated November 1, 2021 (Endo International plc, Filed With SEC on March 1, 2022)
- Retention Agreement between Endo and Matthew J. Maletta, dated November 1, 2021 (Endo International plc, Filed With SEC on March 1, 2022)
- Retention Agreement between Endo and Mark T. Bradley, dated November 1, 2021 (Endo International plc, Filed With SEC on March 1, 2022)
- Retention Agreement between Endo and Blaise Coleman, dated November 1, 2021 (Endo International plc, Filed With SEC on March 1, 2022)
- Form of Retention Agreement (Cara Therapeutics, Inc., Filed With SEC on March 1, 2022)
- Tricida, Inc. Executive Retention Agreement Template Amendment (Tricida, Inc., Filed With SEC on November 8, 2021)
- June 21, 2019 Retention Agreement with Douglas Plassche (ELITE PHARMACEUTICALS INC, Filed With SEC on June 14, 2021)
- Retention Agreement entered into on December 3, 2020, by and between Viatris Inc. and Anthony Mauro (Upjohn Inc, Filed With SEC on March 1, 2021)
- Retention Agreement entered into on December 3, 2020, by and between Viatris Inc. and Rajiv Malik (Upjohn Inc, Filed With SEC on March 1, 2021)
- Retention Agreements by and between Tilray and each of Michael Kruteck and Jon Levin dated December 18, 2020 (Tilray, Inc., Filed With SEC on December 21, 2020)
- Retention agreement, dated October 29, 2020 between Acasti Pharma Inc. and Pierre Lemieux (Acasti Pharma Inc., Filed With SEC on November 16, 2020)
- Retention agreement, dated October 27, 2020, between Acasti Pharma Inc. and Jan DAlvise (Acasti Pharma Inc., Filed With SEC on November 16, 2020)
- Tricida, Inc. Executive Retention Agreement Template (Tricida, Inc., Filed With SEC on November 9, 2020)
- Retention Agreement, dated August 5, 2020, by and between Nabriva Therapeutics US, Inc. and Jennifer Schranz (Nabriva Therapeutics plc, Filed With SEC on November 5, 2020)
- EXECUTIVE RETENTION AGREEMENT (Supernus Pharmaceuticals, Inc., Filed With SEC on October 5, 2020)
- June 21, 2019 Retention Agreement with Douglas Plassche (ELITE PHARMACEUTICALS INC, Filed With SEC on June 29, 2020)
- Key Employee Retention Plan (Sienna Biopharmaceuticals, Inc., Filed With SEC on November 12, 2019)
- Management Retention Plan Letter by and between Sienna Biopharmaceuticals, Inc. and Timothy K. Andrews, dated as of September 11, 2019 (Sienna Biopharmaceuticals, Inc., Filed With SEC on November 12, 2019)
- Management Retention Plan Letter by and between Sienna Biopharmaceuticals, Inc. and Paul Lizzul, dated as of September 11, 2019 (Sienna Biopharmaceuticals, Inc., Filed With SEC on November 12, 2019)
- Management Retention Plan Letter by and between Sienna Biopharmaceuticals, Inc. and Alexander Azoy, dated as of September 11, 2019 (Sienna Biopharmaceuticals, Inc., Filed With SEC on November 12, 2019)
- Management Retention Plan Letter by and between Sienna Biopharmaceuticals, Inc. and Frederick C. Beddingfield III, dated as of September 11, 2019 (Sienna Biopharmaceuticals, Inc., Filed With SEC on November 12, 2019)
- Trevi Therapeutics, Inc. Executive Separation Benefits and Retention Plan (Trevi Therapeutics, Inc., Filed With SEC on September 24, 2019)
- Option Grant Notice, dated May 17, 2019, to Pete Buzy (retention grant) (Catalent Inc, Filed With SEC on August 27, 2019)
- Form of Retention Premium Award (Akorn, Filed With SEC on December 17, 2018)
- Form of Amendment to Executive Retention Agreement (Supernus Pharmaceuticals, Inc., Filed With SEC on May 11, 2018)
